Ausun Pharm
SHA:603229Is this your company? Claim your profile to update info and connect with investors.
Claim profileOverview
A publicly traded Chinese pharmaceutical company specializing in complex small molecule and peptide APIs, formulations, and CDMO services for global markets.
OncologyImmunologyMetabolic DiseasesCardiovascularInfectious Disease
Technology Platform
Advanced synthetic chemistry platform specializing in complex chiral small molecules, high-end fluorine chemistry, prostaglandins, and peptide compounds, with a focus on technically challenging APIs and intermediates.
Opportunities
Growth opportunities include expanding its high-margin CDMO services for global pharma clients, leveraging its peptide synthesis capabilities, and scaling its proprietary finished dosage form business through its Qizheng subsidiary.
Risk Factors
Key risks include intense competition in the Chinese API/CDMO sector, potential pricing pressure, reliance on global regulatory approvals maintaining inspection status, and the capital-intensive nature of capacity expansion.
Competitive Landscape
Competes with other Chinese API/CDMO leaders like WuXi AppTec (STA), Pharmaron, and Porton. Differentiation is based on expertise in specific complex chemical niches (e.g., chiral molecules, peptides), a strong track record of global regulatory compliance, and an integrated model from intermediates to formulations.